JP2024116283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024116283A5 JP2024116283A5 JP2024093451A JP2024093451A JP2024116283A5 JP 2024116283 A5 JP2024116283 A5 JP 2024116283A5 JP 2024093451 A JP2024093451 A JP 2024093451A JP 2024093451 A JP2024093451 A JP 2024093451A JP 2024116283 A5 JP2024116283 A5 JP 2024116283A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- binding agent
- bispecific binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2021/066141 | 2021-06-15 | ||
| PCT/EP2021/066141 WO2022262959A1 (en) | 2021-06-15 | 2021-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
| JP2023577405A JP7513854B2 (ja) | 2021-06-15 | 2022-06-15 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
| PCT/EP2022/066299 WO2022263508A1 (en) | 2021-06-15 | 2022-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577405A Division JP7513854B2 (ja) | 2021-06-15 | 2022-06-15 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024116283A JP2024116283A (ja) | 2024-08-27 |
| JP2024116283A5 true JP2024116283A5 (https=) | 2025-06-20 |
Family
ID=77519090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577405A Active JP7513854B2 (ja) | 2021-06-15 | 2022-06-15 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
| JP2024093451A Pending JP2024116283A (ja) | 2021-06-15 | 2024-06-10 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577405A Active JP7513854B2 (ja) | 2021-06-15 | 2022-06-15 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11739145B2 (https=) |
| EP (1) | EP4355428A1 (https=) |
| JP (2) | JP7513854B2 (https=) |
| KR (1) | KR20240032847A (https=) |
| CN (1) | CN117858906A (https=) |
| AR (1) | AR126154A1 (https=) |
| AU (1) | AU2022292895A1 (https=) |
| BR (1) | BR112023026566A2 (https=) |
| CA (1) | CA3222300A1 (https=) |
| CL (1) | CL2023003725A1 (https=) |
| CO (1) | CO2023017378A2 (https=) |
| IL (1) | IL308072A (https=) |
| MX (1) | MX2023014666A (https=) |
| TW (1) | TW202317624A (https=) |
| WO (2) | WO2022262959A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| JP2026501506A (ja) * | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2025120866A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| TW202541837A (zh) * | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025120867A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| PE20171324A1 (es) * | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
| US20230192903A1 (en) * | 2020-05-29 | 2023-06-22 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody against cldn18.2 and cd3 |
-
2021
- 2021-06-15 WO PCT/EP2021/066141 patent/WO2022262959A1/en not_active Ceased
-
2022
- 2022-06-15 MX MX2023014666A patent/MX2023014666A/es unknown
- 2022-06-15 JP JP2023577405A patent/JP7513854B2/ja active Active
- 2022-06-15 AR ARP220101578A patent/AR126154A1/es unknown
- 2022-06-15 CN CN202280042413.9A patent/CN117858906A/zh active Pending
- 2022-06-15 TW TW111122151A patent/TW202317624A/zh unknown
- 2022-06-15 BR BR112023026566A patent/BR112023026566A2/pt unknown
- 2022-06-15 CA CA3222300A patent/CA3222300A1/en active Pending
- 2022-06-15 EP EP22750661.5A patent/EP4355428A1/en active Pending
- 2022-06-15 WO PCT/EP2022/066299 patent/WO2022263508A1/en not_active Ceased
- 2022-06-15 AU AU2022292895A patent/AU2022292895A1/en active Pending
- 2022-06-15 KR KR1020247001571A patent/KR20240032847A/ko active Pending
- 2022-06-15 IL IL308072A patent/IL308072A/en unknown
- 2022-12-06 US US18/062,465 patent/US11739145B2/en active Active
-
2023
- 2023-07-05 US US18/347,361 patent/US12378313B2/en active Active
- 2023-12-13 CL CL2023003725A patent/CL2023003725A1/es unknown
- 2023-12-14 CO CONC2023/0017378A patent/CO2023017378A2/es unknown
-
2024
- 2024-06-10 JP JP2024093451A patent/JP2024116283A/ja active Pending
-
2025
- 2025-07-11 US US19/267,078 patent/US20260035458A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024116283A5 (https=) | ||
| JP2023509448A5 (https=) | ||
| JP2025011178A5 (https=) | ||
| Deyev et al. | Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design | |
| JP2022512653A5 (https=) | ||
| JP2024167313A5 (https=) | ||
| JP2022061992A5 (https=) | ||
| JP2025160458A5 (https=) | ||
| JP2018518540A5 (https=) | ||
| JP2023549537A5 (https=) | ||
| US20100158925A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| JP2019536430A5 (https=) | ||
| JP2017527274A5 (https=) | ||
| JP2021515798A5 (https=) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2018502050A5 (https=) | ||
| JP2021523913A5 (https=) | ||
| JP2020522474A5 (https=) | ||
| JP2023516004A5 (https=) | ||
| JP2021522347A5 (https=) | ||
| JP2021094022A5 (https=) | ||
| JP2025032102A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2024542194A5 (https=) | ||
| JP2024016024A5 (https=) |